Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Johnson & Johnson: Clinical study of potential coronavirus vaccine could start by end of year

By Chris Newmarker | March 13, 2020

Coronavirus COVID-19 CDC

[Coronavirus image courtesy of CDC]

Johnson & Johnson (NYSE:JNJ) said today that its Janssen Pharmaceutical Cos. has forged a partnership with the Beth Israel Deaconess Medical Center (BIDMC) to support coronavirus vaccine development.

Janssen and the virology lab led by Dr. Dan Barouch at BIDMC have started preclinical testing of multiple vaccine prospects, with the goal of identifying a COVID-19 vaccine candidate for clinical trials by the end of the month. A Phase 1 clinical study of the potential vaccine candidate could start by the end of the year.

Janssen is already preparing to upscale production and manufacturing capacities to meet global needs once the vaccine is available.

“It is critical to work with the best scientific minds as we look to rapidly identify and develop solutions to the COVID-19 outbreak,” said Dr. Paul Stoffels, executive committee vice chair and chief scientific officer at Johnson & Johnson.

“We are grateful for talented and experienced collaboration partners like Dan Barouch and his team at BIDMC. By mobilizing our collective resources, we believe we can leverage the top science and cutting-edge capabilities to respond to this pandemic,” Stoffels said in a news release.

Janssen’s coronavirus vaccine development will utilize the company’s AdVac and PER.C6 technologies to rapidly upscale production of an optimal vaccine candidate, according to the company. The company has already used the technology to develop its investigational Ebola (which also utilizes its MVA-BN technology), Zika, RSV and HIV vaccines.

The Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center worked closely with Janssen on developing the Zika and HIV vaccines.

“We are currently evaluating a series of potential vaccine candidates for COVID-19,” Barouch said. “This collaboration with Janssen is aimed at the development of a COVID-19 vaccine that would allow for rapid development, large-scale manufacturing, and global delivery.”

Johnson & Johnson’s Janssen has already been collaborating on COVID-19 vaccine development with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services.

Janssen is also screening its library of antiviral molecules to accelerate the discovery of potential COVID-19 treatments and provide relief for people around the world.

For more information on Johnson & Johnson’s multipronged response to identifying critical solutions to the COVID-19 outbreak, please visit: www.jnj.com/coronavirus.


Filed Under: Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: Beth Israel Deaconess Medical Center, coronavirus, Janssen Pharmaceutical Cos., Johnson & Johnson
 

Comments

  1. Subir Kumar Ghosh says

    March 15, 2020 at 8:00 am

    Excellent progress to save humankind all over the world from the deadly attack of COVID-19, Coronavirus attack. Hats off to Johnson & Johnson and all its partners in their noble work to save the sufferings of humanity.

    Log in to Reply
  2. Jouy says

    March 15, 2020 at 10:07 am

    Hi
    If this virus comes from bats, as they say, has it ever been observed, studied their environment to know what means they have to counter it, to cure it?
    Best regards

    Log in to Reply
  3. Jennifer Rette says

    April 2, 2020 at 1:19 am

    Why did it take so long, several months, from identifying the vaccine candidate to start a phase 1 clinical trial?

    Log in to Reply

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

CNS
The CNS drug development drum beat is getting louder
DeepMind
7 ways DeepMind’s AlphaFold is being used in life sciences
Biomarker
Bioanalytical method development and validation using Quanterix’s Simoa platform 
FDA logo
FDA could approve MDMA and psilocybin in 2 years

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50